Cancer patients get lifeline to continue Life-Extending drug

NCT ID NCT04421963

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study allows ovarian and breast cancer patients who were benefiting from olaparib treatment in a previous clinical trial to continue receiving the medication. The program provides ongoing access to the drug for 185 patients who show continued clinical improvement. Participants will receive treatment indefinitely until they no longer benefit or experience significant side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Boca Raton, Florida, 33486, United States
Research Site

Towson, Maryland, 21204, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

Minneapolis, Minnesota, 55407, United States
Research Site

Basking Ridge, New Jersey, 07920, United States
Research Site

Hackensack, New Jersey, 07601, United States
Research Site

New York, New York, 10032, United States
Research Site

The Bronx, New York, 10461, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Pittsburgh, Pennsylvania, 15224, United States
Research Site

Willow Grove, Pennsylvania, 19090, United States
Research Site

Providence, Rhode Island, 02905, United States
Research Site

Germantown, Tennessee, 38138, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Leuven, 3000, Belgium
Research Site

Namur, 5000, Belgium
Research Site

Rio de Janeiro, 22793-080, Brazil
Research Site

Plovdiv, 4000, Bulgaria
Research Site

Plovdiv, 4004, Bulgaria
Research Site

Sofia, 1330, Bulgaria
Research Site

Halifax, Nova Scotia, B3H 1V7, Canada
Research Site

Kingston, Ontario, K7L 2V7, Canada
Research Site

Mississauga, Ontario, L5M 2N1, Canada
Research Site

Ottawa, Ontario, K1H 8L6, Canada
Research Site

Toronto, Ontario, M4N 3M5, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Montreal, Quebec, H1T 2M4, Canada
Research Site

Montreal, Quebec, H2X 0A9, Canada
Research Site

Montreal, Quebec, H3T 1E2, Canada
Research Site

Montreal, Quebec, H4A-3J1, Canada
Research Site

Québec, Quebec, G1S 4L8, Canada
Research Site

Changchun, 130021, China
Research Site

Brno, 625 00, Czechia
Research Site

Brno, 656 53, Czechia
Research Site

Olomouc, 779 00, Czechia
Research Site

Ostrava Poruba, 708 52, Czechia
Research Site

Prague, 128 08, Czechia
Research Site

Prague, 150 06, Czechia
Research Site

Aalborg, 9000, Denmark
Research Site

Kuopio, 70210, Finland
Research Site

Lille, 59020, France
Research Site

Lyon, 69373, France
Research Site

Plérin, 22190, France
Research Site

Villejuif, 94800, France
Research Site

Dresden, 1307, Germany
Research Site

Budapest, 1032, Hungary
Research Site

Budapest, 1122, Hungary
Research Site

Haifa, 31096, Israel
Research Site

Jerusalem, 91031, Israel
Research Site

Jerusalem, 91120, Israel
Research Site

Petah Tikva, 49100, Israel
Research Site

Ramat Gan, 5265601, Israel
Research Site

Tel Aviv, 6423906, Israel
Research Site

Ancona, 60020, Italy
Research Site

Bologna, 40138, Italy
Research Site

Brescia, 25123, Italy
Research Site

Candiolo, 10060, Italy
Research Site

Catania, 95126, Italy
Research Site

Lecce, 73100, Italy
Research Site

Lecco, 23900, Italy
Research Site

Milan, 20132, Italy
Research Site

Milan, 20141, Italy
Research Site

Napoli, 80131, Italy
Research Site

Padua, 35128, Italy
Research Site

Roma, 00168, Italy
Research Site

Torino, 10128, Italy
Research Site

Verona, 37134, Italy
Research Site

Bialystok, 15-027, Poland
Research Site

Grzepnica, 72-003, Poland
Research Site

Lublin, 20-090, Poland
Research Site

Olsztyn, 10-561, Poland
Research Site

Poznan, 60-569, Poland
Research Site

Poznan, 61-866, Poland
Research Site

Lisbon, 1649-035, Portugal
Research Site

Porto, 4200-072, Portugal
Research Site

Saint Petersburg, 197758, Russia
Research Site

Ljubljana, 1000, Slovenia
Research Site

Seoul, 01812, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06273, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 6351, South Korea
Research Site

Badalona, 08916, Spain
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 8907, Spain
Research Site

Barcelona, ?08041, Spain
Research Site

Córdoba, 14004, Spain
Research Site

Donostia / San Sebastian, 20014, Spain
Research Site

Granada, 18014, Spain
Research Site

Madrid, 28027, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28046, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Valencia, 46026, Spain
Research Site

Vigo, 36312, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Lund, 22185, Sweden
Research Site

Taipei, 112, Taiwan
Research Site

Ankara, 06230, Turkey (Türkiye)
Research Site

Istanbul, 34093, Turkey (Türkiye)
Research Site

Şahinbey, 27310, Turkey (Türkiye)
Research Site

Birmingham, B18 7QH, United Kingdom
Research Site

Edinburgh, EH4 2XU, United Kingdom
Research Site

Glasgow, G12 OYN, United Kingdom
Research Site

Hull, HU16 5JQ, United Kingdom
Research Site

London, SW3 6JJ, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Taunton, TA1 5DA, United Kingdom

Conditions

Explore the condition pages connected to this study.

BREAST CANCER OVARIAN CANCER